보건복지부 영문홈페이지

Agreement on Joint Development of Global Anti-cancer Drugs between National Cancer Center’s New Anti-Cancer Drug Development Program and a Multinational Pharmaceutical Firm

 

- Joint research begins to secure global competitiveness in the new anti-cancer drug development area

 

“Bridging & Development Program Cancer Therapeutics with System Integration (Program

Manager: Kim, In Cheol)” led by National Cancer Center (President Lee, Jin Soo) and designated

by Ministry of Health and Welfare informed on 26^th that it reached a material transfer agreement

(MTA) with Sanofi Aventis Korea (CEO: Jean-Marie Arnaud, http://www.sanofi.co.kr) for joint 

follow-on development of the candidate substance for new anti-cancer drug that it was handed

over by a government-funded research institute.

 

According to this agreement, the program will conduct all clinical trials for toxicity test on the

candidate substance for new anti-drug that it agreed to further develop and Sanofi Aventis Korea

will carry out a joint research to verify its efficacy.  

 

Program Manager Kim, In Cheol spoke of the significance of this agreement, saying “joint

development with a multinational pharmaceutical firm is the most effective way for us to

overcome Korea’s limited resources and infrastructure for new drug development and secure

global competitiveness in the new drug area. This agreement marks the first step in such

endeavor.”   

 

National Cancer Center President Lee, Jin Soo said, “I will make sure to provide the best support

as president of the research center leading this program so that the candidate substance

selected by the program will be successfully developed into a new global anti-cancer drug.”   

 

Sanofi-Aventis Korea CEO Jean-Marie Arnaud said, “I hope this agreement on joint development

with National Cancer Center that has been leading the high-level cancer research and treatment

of cancer patients will be an opportunity to bring forward the development of innovative anti

cancer drug in Korea,” and added, “Sanofi, as a leading company in the research and

development area, will make contribution to the growth of the local medicine and pharmaceutical

areas through research cooperation for new drug development with Korea’s renowned research

institutes.”

 

The program has been conducting a follow-on development of five candidate substances that

have selected among substances for anti-cancer drugs submitted by Korean academic,

industrial and research organizations and entities since its foundation in last June. Currently, it is

carrying out an evaluation on the candidate substances that have been submitted through the

second contest.

 

Bridging & Development Program Cancer Therapeutics with System Integration designated by

Ministry of Health and Welfare is aiming to carry out a technical transfer of four

global anti-cancer drug substances for which the initial clinical trial will have been

completed by investing around 240 billion won (including 120 billion won of private

investment) over the next five years.